Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Vitamin D and Severe Asthma Exacerbations
A Phase I Trial for Children With Vitamin D Insufficiency and High Risk of Severe Asthma Exacerbations
Status: Enrolling
Updated:  8/9/2013
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Vitamin D and Severe Asthma Exacerbations
A Phase I Trial for Children With Vitamin D Insufficiency and High Risk of Severe Asthma Exacerbations
Status: Enrolling
Updated: 8/9/2013
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Los Angeles, Huntington Beach, San Jose, CA
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Los Angeles, Huntington Beach, San Jose, CA
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Colorado Springs, Denver, CO
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Colorado Springs, Denver, CO
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Waterbury, CT
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Waterbury, CT
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Miami, Tallahassee, FL
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Miami, Tallahassee, FL
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Albany, GA
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Albany, GA
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
South Bend, IN
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
South Bend, IN
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Metairie, LA
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Metairie, LA
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Bangor, ME
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Bangor, ME
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Bethesda, MD
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Bethesda, MD
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
North Dartmouth, MA
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
St. Louis, MO
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
St. Louis, MO
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Ohmaha, Bellevue, NE
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Ohmaha, Bellevue, NE
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Rochester, NY
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Rochester, NY
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Cincinnati, OH
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Cincinnati, OH
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Oklahoma City, OK
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Eugene, Medford, OR
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Eugene, Medford, OR
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Providence, Warwick, RI
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Providence, Warwick, RI
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Spartanburg, Summerville, SC
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Spartanburg, Summerville, SC
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
San Antonio, TX
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
San Antonio, TX
Click here to add this to my saved trials
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated:  8/12/2013
Cytos Investigator Sites
mi
from
Richmond, VA
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Status: Enrolling
Updated: 8/12/2013
Cytos Investigator Sites
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.
A Double-Blind, Randomized, Parallel Group, Placebo-controlled Study to Compare the Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo on Patients With Mild to Moderate Persistent Asthma.
Status: Enrolling
Updated:  9/7/2013
California Allergy and Asthma Medical Group, Inc.
mi
from
Los Angeles, CA
Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.
A Double-Blind, Randomized, Parallel Group, Placebo-controlled Study to Compare the Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo on Patients With Mild to Moderate Persistent Asthma.
Status: Enrolling
Updated: 9/7/2013
California Allergy and Asthma Medical Group, Inc.
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
University of Arizona College of Medicine
mi
from
Tucson, AZ
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
University of Arizona College of Medicine
mi
from
Tucson, AZ
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
UCSF Benioff Children's Hospital
mi
from
San Francisco, CA
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
UCSF Benioff Children's Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
National Jewish Health
mi
from
Denver, CO
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
Emroy University
mi
from
Atlanta, GA
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
Emroy University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
Rush University Medical Center/Stroger Hospital
mi
from
Chicago, IL
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
Rush University Medical Center/Stroger Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
Children's Hospital - Boston
mi
from
Boston, MA
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
Children's Hospital - Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
St. Louis Children's Hospital
mi
from
St. Louis, MO
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
St. Louis Children's Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
Rainbow Babies and Children's Hospital, Case Western Reserve University
mi
from
Cleveland, OH
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
Rainbow Babies and Children's Hospital, Case Western Reserve University
mi
from
Cleveland, OH
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
University of Virginia Health System
mi
from
Charlottesville, VA
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated:  10/11/2013
University of Wisconsin-Madison
mi
from
Madison, WI
Individualized Therapy For Asthma in Toddlers
Individualized Therapy For Asthma in Toddlers
Status: Enrolling
Updated: 10/11/2013
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated:  10/11/2013
University of California, San Francisco, Adult
mi
from
San Francisco, CA
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated: 10/11/2013
University of California, San Francisco, Adult
mi
from
San Francisco, CA
Click here to add this to my saved trials
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated:  10/11/2013
National Jewish Health
mi
from
Denver, CO
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated: 10/11/2013
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated:  10/11/2013
Northwestern Memorial Hospital
mi
from
Chicago, IL
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated: 10/11/2013
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated:  10/11/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated: 10/11/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated:  10/11/2013
Washington University
mi
from
St. Louis, MO
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated: 10/11/2013
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated:  10/11/2013
Duke University School of Medicine
mi
from
Durham, NC
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated: 10/11/2013
Duke University School of Medicine
mi
from
Durham, NC
Click here to add this to my saved trials
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated:  10/11/2013
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated: 10/11/2013
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated:  10/11/2013
University of Pittsburgh, Adult
mi
from
Pittsburgh, PA
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated: 10/11/2013
University of Pittsburgh, Adult
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated:  10/11/2013
University of Wisconsin
mi
from
Madison, WI
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment
Status: Enrolling
Updated: 10/11/2013
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
The Ohio State University Asthma Registry
The Ohio State University Asthma Registry
Status: Enrolling
Updated:  11/18/2013
Ohio State University
mi
from
Columbus, OH
The Ohio State University Asthma Registry
The Ohio State University Asthma Registry
Status: Enrolling
Updated: 11/18/2013
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
Status: Enrolling
Updated:  11/21/2013
GSK Investigational Site
mi
from
Birmingham, AL
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
Status: Enrolling
Updated: 11/21/2013
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
Status: Enrolling
Updated:  11/21/2013
GSK Investigational Site
mi
from
Mobile, AL
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
Status: Enrolling
Updated: 11/21/2013
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
Status: Enrolling
Updated:  11/21/2013
GSK Investigational Site
mi
from
Little Rock, AR
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
Status: Enrolling
Updated: 11/21/2013
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
Status: Enrolling
Updated:  11/21/2013
GSK Investigational Site
mi
from
Huntington Beach, CA
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
Status: Enrolling
Updated: 11/21/2013
GSK Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
Status: Enrolling
Updated:  11/21/2013
GSK Investigational Site
mi
from
Long Beach, CA
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy
Status: Enrolling
Updated: 11/21/2013
GSK Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials